Alebund Pharmaceuticals Adopts Fully Electronic Dissemination of Corporate Communications

Bulletin Express07-22

Alebund Pharmaceuticals (Jiangsu) Limited (“Alebund”) announced that, in line with Rule 2.07A of the Hong Kong Stock Exchange’s paperless listing regime effective 31 December 2023, the company will switch to electronic dissemination of all future corporate communications.

Key points 1. Scope of documents: The change covers directors’ reports, annual and interim reports (and summaries where applicable), meeting notices, listing documents, circulars and proxy forms. 2. Access channels: Both English and Chinese versions of every future document will be posted on Alebund’s website (www.alebund.com) and the HKExnews platform (www.hkexnews.hk); printed copies will no longer be mailed by default. 3. Actionable communications: Shareholders are encouraged to submit a functional email address—by scanning the personalised QR code on the reply form or returning the form to Computershare Hong Kong Investor Services Limited—to receive actionable corporate communications electronically. 4. Default arrangement: If no email address is provided, actionable communications will be sent in printed form until an address is registered. 5. Opt-out option: Shareholders preferring hard copies may request printed materials via the reply form or by emailing Alebund.ecom@computershare.com.hk. Each such request remains valid for one year from receipt. 6. Enquiries: The share registrar’s hotline is +852 2862 8555, available Monday to Friday, 9:00 a.m.–6:00 p.m. (Hong Kong time).

Dr. Gavin Guoyao Xia, Chairman, Executive Director and Chief Executive Officer, signed the notice dated 22 July 2026 on behalf of the board.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment